Clinical Trials Browser

Phase 2 × Retinoblastoma × 1 year × Clear all

Retinoblastoma

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT05504291 2026-02-17

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Phase 2 Recruiting

26 enrolled

Other solid neoplasm

Retinoblastoma

NCT02870907 2026-01-07

RB SFCE 09

Phase 2 Active not recruiting

195 enrolled

Other solid neoplasm

Retinoblastoma

NCT02866136 2025-11-24

RETINO2011

Phase 2 Active not recruiting

133 enrolled

Other solid neoplasm

Retinoblastoma, Retinal Neoplasms

NCT04040205 2025-07-20

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Phase 2 Recruiting

44 enrolled

Other solid neoplasmSarcoma

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

Clinical Trials

Retinoblastoma Phase II Expanded Access Clinical Trial

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

RB SFCE 09

RETINO2011

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration